Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 72.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 107,382 shares of the biopharmaceutical company’s stock after selling 277,269 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Gilead Sciences were worth $8,699,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Tompkins Financial Corp raised its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Sachetta LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $30,000. Finally, Rakuten Securities Inc. acquired a new stake in Gilead Sciences during the fourth quarter worth about $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 2.4 %

Shares of Gilead Sciences stock opened at $65.06 on Monday. The firm has a market cap of $81.06 billion, a price-to-earnings ratio of 180.72, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The company’s 50-day simple moving average is $66.03 and its 200-day simple moving average is $73.32. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the business posted $1.37 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.73%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of analyst reports. Barclays decreased their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 price target on shares of Gilead Sciences in a report on Friday. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, TD Cowen reduced their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.